238 related articles for article (PubMed ID: 28103976)
21. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
22. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
Croegaert K; Kolesar JM
Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
[TBL] [Abstract][Full Text] [Related]
23. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.
Yi ES; Chung JH; Kulig K; Kerr KM
Mol Diagn Ther; 2012 Jun; 16(3):143-50. PubMed ID: 22506598
[TBL] [Abstract][Full Text] [Related]
24. The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy.
Zhang NN; Liu YT; Ma L; Wang L; Hao XZ; Yuan Z; Lin DM; Li D; Zhou YJ; Lin H; Han XH; Sun Y; Shi Y
PLoS One; 2014; 9(1):e84501. PubMed ID: 24404167
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of patients with ALK gene rearranged non-small cell lung cancer
after resistance to crizotinib].
Jiang T; Zhou C
Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):69-74. PubMed ID: 25676398
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
Chuang JC; Neal JW; Niu XM; Wakelee HA
Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
[TBL] [Abstract][Full Text] [Related]
27. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
[TBL] [Abstract][Full Text] [Related]
28. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
Sasaki T; Koivunen J; Ogino A; Yanagita M; Nikiforow S; Zheng W; Lathan C; Marcoux JP; Du J; Okuda K; Capelletti M; Shimamura T; Ercan D; Stumpfova M; Xiao Y; Weremowicz S; Butaney M; Heon S; Wilner K; Christensen JG; Eck MJ; Wong KK; Lindeman N; Gray NS; Rodig SJ; Jänne PA
Cancer Res; 2011 Sep; 71(18):6051-60. PubMed ID: 21791641
[TBL] [Abstract][Full Text] [Related]
29. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
30. Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
Crystal AS; Shaw AT; Sequist LV; Friboulet L; Niederst MJ; Lockerman EL; Frias RL; Gainor JF; Amzallag A; Greninger P; Lee D; Kalsy A; Gomez-Caraballo M; Elamine L; Howe E; Hur W; Lifshits E; Robinson HE; Katayama R; Faber AC; Awad MM; Ramaswamy S; Mino-Kenudson M; Iafrate AJ; Benes CH; Engelman JA
Science; 2014 Dec; 346(6216):1480-6. PubMed ID: 25394791
[TBL] [Abstract][Full Text] [Related]
31. ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options.
Steuer CE; Ramalingam SS
Cancer; 2014 Aug; 120(16):2392-402. PubMed ID: 24853389
[TBL] [Abstract][Full Text] [Related]
32. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Noh KW; Lee MS; Lee SE; Song JY; Shin HT; Kim YJ; Oh DY; Jung K; Sung M; Kim M; An S; Han J; Shim YM; Zo JI; Kim J; Park WY; Lee SH; Choi YL
J Pathol; 2017 Nov; 243(3):307-319. PubMed ID: 28741662
[TBL] [Abstract][Full Text] [Related]
33. A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer.
Biya J; Caramella C; Lindsay CR; Planchard D; Besse B
J Thorac Oncol; 2015 Jun; 10(6):e44-5. PubMed ID: 26001149
[TBL] [Abstract][Full Text] [Related]
34. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
35. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
36. [Horizon
--interpretation of ALK-positive non-small cell lung cancer Chinese story].
Liu X
Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):59-60. PubMed ID: 25676396
[No Abstract] [Full Text] [Related]
37. ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer.
Gerber DE; Oxnard GR; Govindan R
Clin Pharmacol Ther; 2015 May; 97(5):447-50. PubMed ID: 25677079
[TBL] [Abstract][Full Text] [Related]
38. Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.
Gadgeel SM
Lung Cancer; 2017 Jul; 109():147-148. PubMed ID: 28365051
[No Abstract] [Full Text] [Related]
39. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
40. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
Camidge DR; Skokan M; Kiatsimkul P; Helfrich B; Lu X; Barón AE; Schulte N; Maxson D; Aisner DL; Franklin WA; Doebele RC; Varella-Garcia M
Cancer; 2013 Nov; 119(22):3968-75. PubMed ID: 24022839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]